FDA Warning Letter to Pharmathen International S.A. (2026-05-27) — CGMP/Active Pharmaceutical Ingredient (API)/Adulterated
Letter issued · posted to fda.gov .
Subject as published: CGMP/Active Pharmaceutical Ingredient (API)/Adulterated
TL;DR
The short version: FDA issued a Warning Letter to Pharmathen International S.A. on 2026-05-27 citing: CGMP/Active Pharmaceutical Ingredient (API)/Adulterated. Full letter: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/pharmathen-international-sa-723680-05272026
Argus analysis
Pharmathen International S.A. (MARCS-CMS 723680, FEI 3009961173) received an FDA Warning Letter dated May 27, 2026 from the Center for Drug Evaluation and Research (CDER). The letter cites: CGMP/Active Pharmaceutical Ingredient (API)/Adulterated. FDA posts Warning Letters to fda.gov after an internal review period; this one was made public on June 16, 2026.
CGMP citations typically reference 21 CFR Part 211 (finished pharmaceuticals) or Part 111 (dietary supplements), covering subjects such as identity testing of incoming components, validated cleaning procedures, batch-failure investigations, and stability program design. Repeat or systemic findings are what typically drive FDA toward import alert or consent decree escalation.
FDA Warning Letters typically specify a 15-working-day response window for the recipient to detail corrective actions. Compliance teams at peer companies in the same CGMP (Current Good Manufacturing Practice) category commonly use a newly published letter as a prompt to re-check their own procedures against the same citation, and to watch fda.gov for a close-out letter confirming the cited firm's corrective action was accepted — or, absent one, for escalation to import alert, injunction, or product seizure.
Severity context
Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
Regulatory background
CGMP citations typically reference 21 CFR Part 211 (drugs) or 21 CFR Part 600 (biologics). Common subjects include identity testing of incoming components (211.84), validated cleaning procedures (211.67), and stability program design (211.166).
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER Pharmathen International S.A. MARCS-CMS 723680 — May 27, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: Via Email Return Receipt Requested Reference #: 320-26-80 Product: Drugs Recipient: Recipient Name Mr. John Pius Nason Recipient Title Group CEO Pharmathen International S.A. 44 Kifissias Ave. 15125 Marousi Attica Greece Issuing Office: Center for Drug Evaluation and Research (CDER) United States Warning Letter 320-26-80 May 27, 2026 Dear Mr. Nason: The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Pharmathen International S.A., FEI 3009961173, at Industrial Park, Sapes Rodopi Prefecture, Block No 5 Rodopi, Evrou, Greece, from November 10 to 21, 2025. This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211). Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B). We reviewed your December 15, 2025, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence. During our inspection, our investigators observed specific violations including, but not limited to, the following. 1. Your firm failed to follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)). The airflow visualization studies (i.e., smoke studies) you performed for the (b)(4) aseptic vial filling line you use to fill sterile powder drug products for the U.S. market did not demonstrate unidirectional airflow. This processing line is housed in an (b)(4) Restricted Access Barrier System ( (b)(4) RABS). For example, during the simulation of the (b)(4) installation, the (b)(4) remained (b)(4) for an extended time. The airflow was observed exiting the filling line area, bouncing off the operator’s chest, and reentering the filling line. This problematic airflow pattern in your (b)(4) RABS creates significant potential for microbial contamination. Notably, our investigators also observed multiples instances of inappropriate aseptic behavior. For example, when removing empty fallen vials, the operator blocked first air, and exposed vials were not discarded. In addition, your smoke studies failed to sufficiently evaluate removal of fallen vials as well as other critical aseptic manipulations. Our inspection also found multiple instances of gram-negative microbes in ISO 5 air samples. It is highly atypical to find gram-negative microbes in an aseptic processing room environment. In one su…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- Is the FDA warning letter to Pharmathen International S.A. publicly available?
- Yes. The full verbatim letter is published at fda.gov. Argus HQ links directly to the source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/pharmathen-international-sa-723680-05272026.
- What does a "critical" severity rating mean for this letter?
- Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
- What is the regulatory background for a CGMP — Current Good Manufacturing Practice warning letter?
- CGMP citations typically reference 21 CFR Part 211 (drugs) or 21 CFR Part 600 (biologics). Common subjects include identity testing of incoming components (211.84), validated cleaning procedures (211.67), and stability program design (211.166).
- What is the standard FDA response window for a warning letter?
- FDA warning letters typically require a written response within 15 working days of receipt, outlining the corrective and preventive actions the company will take.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. $199/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). FDA Warning Letter to Pharmathen International S.A. (2026-05-27) — CGMP/Active Pharmaceutical Ingredient (API)/Adulterated. Digital Empire LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-pharmathen-international-s-a-2026-05-27-cgmp
"FDA Warning Letter to Pharmathen International S.A. (2026-05-27) — CGMP/Active Pharmaceutical Ingredient (API)/Adulterated." Argus HQ Research, Digital Empire LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-pharmathen-international-s-a-2026-05-27-cgmp.
Argus HQ Research. "FDA Warning Letter to Pharmathen International S.A. (2026-05-27) — CGMP/Active Pharmaceutical Ingredient (API)/Adulterated." Digital Empire LLC. Accessed July 13, 2026. https://argushq.ai/fda/warning-letter/fda-wl-pharmathen-international-s-a-2026-05-27-cgmp.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_pharmathen_international_s_a_2026_05_27_cgmp_2026,
title = {FDA Warning Letter to Pharmathen International S.A. (2026-05-27) — CGMP/Active Pharmaceutical Ingredient (API)/Adulterated},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-pharmathen-international-s-a-2026-05-27-cgmp},
note = {Accessed: July 13, 2026}
}